Fig. 2From: Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s diseaseMean (SD) serum crenezumab concentrations after initial dose (weeks 1–5). Each line represents mean crenezumab serum concentration following IV administration; doses of 15 mg/kg (ABBY; BLAZE) and 30–120 mg/kg (GN29632 phase Ib study). Abbreviations: IV intravenous, SD standard deviationBack to article page